NEW YORK (GenomeWeb News) - Sequenom CEO Harry Stylli bought 13,313 shares of the company's stock at an average price of $1.86 per share for total proceeds of $24,964 on Aug. 11, according to documents filed with the Securities and Exchange Commission.
 
Since Aug. 7, he purchased 53,700 shares for total proceeds of $96,565. He currently owns 54,700 shares of Sequenom stock.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.